Tirzepatide vs MK-677
A comprehensive, data-driven comparison of Tirzepatide (Mounjaro) and MK-677 (Ibutamoren). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Tirzepatide Mounjaro, Zepbound | MK-677 Ibutamoren, Nutrobal |
|---|---|---|
| FDA Status | FDA Approved | Phase 2 |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Type 2 diabetes, chronic weight management, and obstructive sleep apnea | Growth hormone optimization and muscle growth |
| Weight Loss % | 22.5% | N/A |
| Monthly Cost | $1,100 - $1,100/mo | $50 - $100/mo |
| Administration | Subcutaneous injection | Oral |
| Typical Dose | 15mg weekly (max dose) | 10-25mg daily |
| Frequency | Weekly | Daily |
| Mechanism | Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric emptying, and decreases appetite | Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Moderate |
| Clinical Trial Phase | Approved | Phase 2 |
Key Differences
- 1Tirzepatide is FDA-approved, while MK-677 is currently phase 2.
- 2Tirzepatide has clinical weight loss data (22.5%), while MK-677 is not primarily indicated for weight loss.
- 3MK-677 is generally more affordable ($50 - $100/mo) compared to Tirzepatide ($1,100 - $1,100/mo).
- 4Tirzepatide is administered via subcutaneous injection, while MK-677 uses oral.
- 5Tirzepatide is dosed weekly, while MK-677 is daily.
- 6Tirzepatide has high-quality evidence, while MK-677 has moderate-quality evidence.
- 7They belong to different categories: Tirzepatide (Weight Loss) vs MK-677 (Growth Hormone).
Which Is Better For...
Tirzepatide
Those seeking an FDA-approved treatment with established safety data
MK-677
More budget-friendly option with lower monthly costs
Tirzepatide
More convenient dosing schedule (weekly)
MK-677
Fewer commonly reported side effects
Tirzepatide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Tirzepatide | $1,100 - $1,100/mo | FDA Approved | Eli Lilly |
| MK-677 | $50 - $100/mo | Phase 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. MK-677 works via Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1. They differ in FDA approval status, efficacy data, and cost.
Tirzepatide has demonstrated 22.5% average weight loss in clinical trials. MK-677 is not primarily used for weight loss.
Tirzepatide typically costs $1,100 - $1,100/mo, while MK-677 costs $50 - $100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Tirzepatide is FDA-approved. MK-677 is not FDA-approved (Phase 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Common side effects of MK-677 include Increased appetite, Water retention, Fatigue. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Tirzepatide is a dual-action peptide approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. In December 2024, Zepbound became the first and only medication approved fo...
View Full Tirzepatide GuideMK-677 (Ibutamoren) is an orally-active growth hormone secretagogue that mimics the action of ghrelin. Unlike peptide injections, it is taken orally and has a long half-life allowing once-daily dosing...
View Full MK-677 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Tirzepatide and MK-677 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.